{"schema_version":"secwatch.filing_event.v1","accession":"0001613103-22-000058","form_type":"8-K","ticker":"MDT","cik":"0001613103","company_name":"Medtronic plc","filed_at":"2022-11-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.403573+00:00","generated_at":"2026-06-21T14:10:32.005199+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Medtronic Q2 FY2023 revenue down 3%; lowers FY2023 EPS guidance to $5.25-$5.30","bullets":["Revenue $7.585B, organic growth +2%; GAAP EPS $0.32 (down 67%), non-GAAP EPS $1.30 (down 2%).","FY2023 non-GAAP EPS guidance cut to $5.25-$5.30; H2 organic revenue growth expected 3.5%-4.0%.","Tax reserve adjustment of $764M from U.S. Tax Court opinion weighed on GAAP earnings.","Segment organic growth: Cardiovascular +4%, Medical Surgical -3%, Neuroscience +5%, Diabetes +3%.","CEO cites slower procedure/supply recovery; executing cost reductions and supply chain improvements."],"urls":{"canonical":"https://secwatch.observer/filing/0001613103-22-000058","json":"https://secwatch.observer/filing/0001613103-22-000058.json","markdown":"https://secwatch.observer/filing/0001613103-22-000058.md","text":"https://secwatch.observer/filing/0001613103-22-000058.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1613103/000161310322000058/0001613103-22-000058-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1613103/000161310322000058/mdt-20221122.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T14:10:32.005199+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7b10e22d0d0bec1d9f1f5a6bd092a5835f303b5b","claim":"Medtronic plc reported second quarter of fiscal year 2023, which ended October 28, 2022 results: revenue $7.585 billion, net income $427 million, EPS $0.32.","evidence_excerpt":"Medtronic plc (NYSE:MDT) today announced financial results for its second quarter of fiscal year 2023, which ended October 28, 2022. Key Highlights • Revenue of $7.6 billion decreased 3% as reported and increased 2% organic • GAAP diluted EPS of $0.32 decreased 67%; non-GAAP diluted EPS of $1.30 decreased 2% • Company updates guidance; expects organic revenue to accelerate in second half","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1613103/000161310322000058/0001613103-22-000058-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter of fiscal year 2023, which ended October 28, 2022"},{"label":"Revenue","value":"$7.585 billion"},{"label":"Net income","value":"$427 million"},{"label":"EPS","value":"$0.32"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}